Replies to post #222 on Fate Therapeutics Inc (FATE)

[NY1972]

I think all NK cells need a ICE like AFM-24.

[jondoeuk]

Identification of novel CAR transmembrane and endodomains for improved persistence and cytotoxicity of NK cell therapies https://www.abstractsonline.com/pp8/#!/10828/presentation/3324

[jondoeuk]

I can see why they chose the targets they did, but it makes little sense to waste resources as there are a lot of (good) therapies targeting CD19, BCMA and HER2 either approved or in development https://www.modulustherapeutics.com/pipeline

Focusing on MTX-202, Catamaran Bio are already further along with CAT-179. It is off-the-shelf, has an optimised CAR for NKs, dominant-negative TGF-B receptor and IL-15, engineered using a non-viral system https://catamaranbio.com/wp-content/uploads/2022/11/Moore_et_al._SITC_2022-poster_final.pdf

They are also working on a number of switch receptors, including https://catamaranbio.com/wp-content/uploads/2022/05/Storer_et_al._ASGCT_2022.pdf

[jondoeuk]

DNA has acquired Modulus Therapeutics' cell therapy platform assets, including their CAR and switch receptor libraries https://www.prnewswire.com/news-releases/ginkgo-bioworks-acquires-modulus-therapeutics-cell-therapy-assets-to-strengthen-next-gen-car-designs-302105056.html